Antihypertensive Agent

CHICAGO — Among adults living in India with elevated BP, three different dual-medication polypills containing combinations of recommended first-line antihypertensive agents effectively lowered ambulatory BP, researchers reported.

An estimated 16 million U.S. adults who qualified for statin and/or antihypertensive therapy would not be eligible for primary prevention under the American Heart Association’s new PREVENT risk calculator, researchers reported in JAMA.

Attaining systolic BP between 110 mm Hg and 130 mm Hg was associated with higher probability of surviving to 90 years of age among women aged 65 years and older, according to results of a real-world study published in Circulation.

ATLANTA — A single subcutaneous dose of zilebesiran, an investigational RNA interference agent, significantly reduced 24-hour mean ambulatory and office systolic BP at 6 months vs. placebo when added to other antihypertensive therapy.

PHILADELPHIA — Zilebesiran, an investigational subcutaneous RNA interference therapeutic, lowered systolic blood pressure at 3 months and sustained the reduction to 6 months, according to results of the phase 2 KARDIA-1 trial.

BOSTON — Data show sleep abnormalities are associated with hypertension; however, antihypertensive medications can in turn disrupt sleep, complicating treatment for patients, according to a speaker.

Compared with monotherapy, usual care or placebo, polypills containing three or four low-dose antihypertensive drugs were associated with greater achievement of target BP and more sustained BP lowering, according to a meta-analysis.

Blood pressure lowering with common antihypertension drugs varies widely among adults with hypertension, yet greater reductions are possible with personalized therapy, researchers reported.

Use of early vs. delayed antihypertensive treatment after onset of acute ischemic stroke to reduce risk for composite case-fatality and major disability at 3 months.

Researchers observed no difference in 3-month functional outcomes or mortality among patients with acute ischemic stroke who underwent early BP-lowering therapy compared with a delayed strategy, a speaker reported.